Abstract | OBJECTIVES: The study reports the final 5-year safety and effectiveness outcomes of the novel abluminal groove-filled biodegradable polymer-coated FIREHAWK sirolimus-eluting stent in a large patient cohort. BACKGROUND: The TARGET clinical program was conducted to evaluate the performance of the FIREHAWK stent, and this objective performance criterion study pooled long-term safety and efficacy data from three TARGET trials for greater statistical power to analyze low-frequency events. METHODS: Patient-level pooled data from 1,007 individuals in the TARGET I randomized controlled trial (n = 227), TARGET I long lesion cohort (n = 50), and TARGET II registry (n = 730) were prospectively collected and analyzed. The primary endpoint, target lesion failure (TLF), was defined as a composite of cardiac death, target vessel myocardial infarction (TV-MI), and ischemia-driven indicated target lesion revascularization (ID-TLR) at 5 years. All patients were exclusively treated with the FIREHAWK stent and had annual follow-up visits for up to 5 years. RESULTS: Among 947 patients (94.0%) who completed the 5-year clinical follow-up, the 5-year TLF event rate was 8.1%; the events included 18 cardiac deaths, 36 TV-MIs, and 33 ID-TLRs. Only four (0.4%) very late probable or definite stent thrombosis events were observed beyond 1 year after stent implantation. In the subgroup analysis, lesion length ≥ 30 mm was associated with higher long-term TLF incidence, while the use of a predilation-sizing-postdilation technique showed no significant effect on long-term outcomes. CONCLUSIONS: Five-year results demonstrate the continuing safety and efficacy of the FIREHAWK Stent, with relatively lower incidence of thrombotic events.
|
Authors | Chongjian Li, Changdong Guan, Ruiyan Zhang, Yuejin Yang, Changsheng Ma, Hui Li, Shaoliang Chen, Yaling Han, Bo Xu, Runlin Gao, TARGET Investigators |
Journal | Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions
(Catheter Cardiovasc Interv)
Vol. 93
Issue S1
Pg. 818-824
(02 15 2019)
ISSN: 1522-726X [Electronic] United States |
PMID | 30565397
(Publication Type: Journal Article)
|
Copyright | © 2018 Wiley Periodicals, Inc. |
Chemical References |
- Cardiovascular Agents
- Sirolimus
|
Topics |
- Absorbable Implants
- Aged
- Cardiovascular Agents
(administration & dosage, adverse effects)
- China
(epidemiology)
- Coronary Artery Disease
(diagnostic imaging, mortality, therapy)
- Coronary Thrombosis
(epidemiology)
- Drug-Eluting Stents
- Female
- Humans
- Incidence
- Male
- Middle Aged
- Myocardial Infarction
(epidemiology)
- Percutaneous Coronary Intervention
(adverse effects, instrumentation, mortality)
- Prospective Studies
- Prosthesis Design
- Randomized Controlled Trials as Topic
- Registries
- Risk Factors
- Sirolimus
(administration & dosage, adverse effects)
- Time Factors
- Treatment Outcome
|